Telmisartan Versus Valsartan in Patients With Hypertension: Effects on Cardiovascular, Metabolic, and Inflammatory Parameters
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Sung Yoon | - |
dc.contributor.author | Kim, Sun Won | - |
dc.contributor.author | Kim, Eung Ju | - |
dc.contributor.author | Kang, Jun Hyuk | - |
dc.contributor.author | Kim, Su A. | - |
dc.contributor.author | Kim, Yun Kyung | - |
dc.contributor.author | Na, Jin Oh | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Lim, Hong Euy | - |
dc.contributor.author | Han, Seong Woo | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Seo, Hong Seog | - |
dc.contributor.author | Oh, Dong Joo | - |
dc.date.accessioned | 2021-09-07T07:53:39Z | - |
dc.date.available | 2021-09-07T07:53:39Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2011-10 | - |
dc.identifier.issn | 1738-5520 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111488 | - |
dc.description.abstract | Background and Objectives: Angiotensin-receptor blockers (ARBs) have beneficial effects on cardiovascular, metabolic, and inflammatory parameters in addition to controlling blood pressure (BP). However, few comparative clinical studies have been conducted with different ARBs. We compared these effects in patients with uncomplicated hypertension who were receiving telmisartan or valsartan. Subjects and Methods: The subjects were patients with essential hypertension (48.4 +/- 9.6 years) who were randomly assigned to take either telmisartan (80 mg/day, n=30) or valsartan (160 mg/day, n=30) for 12 weeks. Their anthropometric, laboratory, vascular, and echocardiographic data were measured at baseline and at the end of the study. Results: Baseline characteristics were not significantly different between the two groups, except for the carotidfemoral pulse wave velocity (cfPWV; telmisartan group vs. valsartan group; 841.2 +/- 131.0 vs. 761.1 +/- 104.4 cm/s, p<0.05). After 12 weeks, BP had fallen to a similar extent with mean reductions in the systolic and diastolic BP of 20.7 +/- 18.1 and 16.3 +/- 13.0 mm Hg (p<0.001, respectively) for the telmisartan and 22.5 +/- 17.0 and 16.8 +/- 9.3 mm Hg (p<0.001, respectively) for the valsartan group. Although the cfPWV and left ventricular mass index (LVMI) fell significantly only with the administration of telmisartan, they were not significantly different when baseline cfPWV was considered. The differences in the cfPWV and LVMI changes from baseline between the two groups were also not significant after adjusting for baseline cfPWV. No significant changes in other vascular, metabolic, or inflammatory parameters were observed with either treatment. Conclusion: The effects of a 12-week treatment with the two ARBs, telmisartan and valsartan, on cardiovascular, metabolic, and inflammatory parameters were not different in patients with uncomplicated hypertension. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC CARDIOLOGY | - |
dc.subject | CONVERTING-ENZYME-INHIBITOR | - |
dc.subject | BLOOD-PRESSURE | - |
dc.subject | MYOCARDIAL FIBROSIS | - |
dc.subject | ARTERIAL STIFFNESS | - |
dc.subject | RECEPTOR BLOCKER | - |
dc.subject | EUROPEAN-SOCIETY | - |
dc.subject | ANGIOTENSIN | - |
dc.subject | GUIDELINES | - |
dc.subject | LOSARTAN | - |
dc.subject | ULTRASOUND | - |
dc.title | Telmisartan Versus Valsartan in Patients With Hypertension: Effects on Cardiovascular, Metabolic, and Inflammatory Parameters | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Eung Ju | - |
dc.contributor.affiliatedAuthor | Na, Jin Oh | - |
dc.contributor.affiliatedAuthor | Choi, Cheol Ung | - |
dc.contributor.affiliatedAuthor | Lim, Hong Euy | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.contributor.affiliatedAuthor | Park, Chang Gyu | - |
dc.contributor.affiliatedAuthor | Seo, Hong Seog | - |
dc.contributor.affiliatedAuthor | Oh, Dong Joo | - |
dc.identifier.doi | 10.4070/kcj.2011.41.10.583 | - |
dc.identifier.scopusid | 2-s2.0-82055169454 | - |
dc.identifier.wosid | 000209079100004 | - |
dc.identifier.bibliographicCitation | KOREAN CIRCULATION JOURNAL, v.41, no.10, pp.583 - 589 | - |
dc.relation.isPartOf | KOREAN CIRCULATION JOURNAL | - |
dc.citation.title | KOREAN CIRCULATION JOURNAL | - |
dc.citation.volume | 41 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 583 | - |
dc.citation.endPage | 589 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001600590 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | CONVERTING-ENZYME-INHIBITOR | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | MYOCARDIAL FIBROSIS | - |
dc.subject.keywordPlus | ARTERIAL STIFFNESS | - |
dc.subject.keywordPlus | RECEPTOR BLOCKER | - |
dc.subject.keywordPlus | EUROPEAN-SOCIETY | - |
dc.subject.keywordPlus | ANGIOTENSIN | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | LOSARTAN | - |
dc.subject.keywordPlus | ULTRASOUND | - |
dc.subject.keywordAuthor | Hypertension | - |
dc.subject.keywordAuthor | Valsartan | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.